This commitment comes on the sidelines of Tamil Nadu Chief Minister visit to United Kingdom and aims to boost AstraZeneca’s Global Innovation & Technology Centre in Chennai focused on advancing technology & innovation efforts in healthcare
Chennai, India - September 5, 2025 - AstraZeneca, a global, science-led, patient-focused pharmaceutical company dedicated to accelerating the delivery of life-changing medicines, today announced a strategic investment of Rs 176 crore, the third such investment in the past two years in India. This new investment is focused on expanding the capabilities and infrastructure at its Global Innovation & Technology Centre (GITC) in Chennai to strengthen its position as a leader in healthcare innovation both globally and in India.
AstraZeneca’s expanded presence in the country will fuel the development of advanced technology capabilities, foster high-value job creation, and deepen collaborations with local talent pools and partners in Tamil Nadu and India. Additionally, this step will help accelerate the delivery of next-generation medicines, support digital and data-driven solutions, and help shape future-ready healthcare ecosystems. "We’re proud to reinforce our commitment to the country’s vibrant scientific and technological community. This new investment reflects our ongoing mission to improve patient lives by embedding cutting-edge technologies into every aspect of our work. Chennai continues to evolve as a vital innovation hub, and our continued growth here demonstrates the state's boundless potential”, said Siva Padmanabhan, Managing Director, AstraZeneca India Private Limited.
The investment supports the growth of AstraZeneca’s world-class technology and innovation teams, including specialists in artificial intelligence, data analytics, machine learning, data science, and supply chain analytics to shape and transform healthcare outcomes. The GITC will benefit immensely from upgraded and additional capacity, designed to enable collaborative research and transformative solutions that address complex healthcare challenges.
Honourable MK Stalin-Chief Minister Tamil Nadu said, "AstraZeneca has played a significant role in shaping an ecosystem that integrates technology with healthcare ultimately changing the way people are accessing healthcare in the country. This additional investment in Chennai is a testament to state’s reputation as a centre of excellence for global innovation. This partnership will generate skilled opportunities, encourage knowledge exchange, and reinforce Tamil Nadu’s status as a premier destination for forward-looking industries."
This initiative will propel AstraZeneca’s efforts to integrate digital transformation into patient care, enhance operational efficiency, and develop new solutions to pressing health issues. By drawing on India’s diverse talent and unique strengths, AstraZeneca reaffirms its vision for a healthier future through science and partnership. AstraZeneca is focused on transforming healthcare for millions of people in India. In addition to its innovative portfolio in specialist disease areas including oncology, cardio-vascular, respiratory and rare disease, the company has a strong hub for technology, global business services as well as research and development in India. Including the GITC, it employs more than 5000 in the country and is continuously shaping talent that is skilled, diverse and future ready.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in four therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory and Rare Disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Completing its 45 years in India, AstraZeneca Pharma India Limited (AZPIL) is focused on bringing innovative medicines faster to patients in India across therapy areas it is present in. Headquartered at Bengaluru, Karnataka in India AZPIL has a workforce of over 600 employees across the country committed to deliver medicines to patients through innovative science and global excellence in development and commercialization.
AstraZeneca India Private Limited (AZIPL) plays a crucial role in driving innovation and technology across the global enterprise. The Global Innovation & Technology Centre (GITC) in Chennai serves as a strategic hub for IT, Global Business Services (GBS), Global supply chain & strategy, supporting core business operations with high-impact, technology-driven solutions. The Global Hub in Bangalore is dedicated to Research & Development (R&D), Global Business Services (GBS), IT & Digital Health capabilities, playing a key role in advancing scientific discovery and innovation within the enterprise.
To know more, please visit www.astrazeneca.com/india or follow us on LinkedIn.
For media queries, please contact, Gunjan Gupta, Lead Corporate Communications & Sustainability, AstraZeneca India | gunjan.gupta1@astrazeneca.com | +91 9663420314